A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). The authors explained that while molecularly targeted therapies like Bruton ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

A new study has given leukemia researchers a powerful new dataset and collection of analytical methods—and a starting point for future research. One common treatment for leukemia is hematopoietic stem ...

This Research Topic is the second volume of the “Unraveling Breast Cancer Complexity: Insights from Single-Cell Sequencing and Spatial Transcriptomics” ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

As treacherous as it is complex, the tumor microenvironment (TME) is composed of different cell types that produce an abundance of cross-talking molecules, extracellular vesicles, and metabolites. All ...

The tumor microenvironment is a battleground where infiltrating immune cells either subdue or promote a cancer, all while cancer cells try to dampen the body’s defenses. 1,2 Scientists have studied ...

Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms. Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm ...